COPENHAGEN (Reuters) – Danish drug maker Novo Nordisk aims to generate sales of its obesity drugs worth more than 25 billion Danish ($3.73 billion) in 2025, the company said at its capital markets day on Thursday.
($1 = 6.7092 Danish crowns)
(Reporting by Nikolaj Skydsgaard; editing by Jason Neely)
